Mode of action of the antitumor compound bruceantin, an inhibitor of protein synthesis.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D004247:DNA / Q000096:biosynthesis; D003864:Depression, Chemical; D005914:Globins / Q000096:biosynthesis; D006367:HeLa Cells / Q000378:metabolism / Q000648:ultrastructure; D006801:Humans; D066298:In Vitro Techniques; D007700:Kinetics; D010616:Phenanthrenes / Q000494:pharmacology*; D010936:Plant Extracts / Q000494:pharmacology; D011132:Polyribosomes / Q000378:metabolism; D014176:Protein Biosynthesis; D012313:RNA / Q000096:biosynthesis / Q000378:metabolism; D011817:Rabbits; D012156:Reticulocytes / Q000378:metabolism; D013329:Structure-Activity Relationship
D000970:Antineoplastic Agents; D010616:Phenanthrenes; D010936:Plant Extracts; D012313:RNA; D005914:Globins; D004247:DNA